Breakthroughs in Diabetes Care

Welcome to our new literature update on laboratory biomarker development in major diseases. Our second edition focuses on diabetes: A digest of cutting-edge publications covering the months of July and August!

Discover the latest breakthroughs in diabetes research, hot off the press. We're diving deep into state-of-the-art biomarkers, identifying game-changing studies, and illuminating new pathways for patient care. Curated to bring only the most clinically relevant data to your practice, this update bridges the gap between academic journals and bedside interventions. Stay ahead of the curve and optimise patient management with our selection of the most impactful recent publications in diabetes care.

 
Recent key publications
 

1) Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation.
Eur Heart J 2023; 44:2335-2345. Silbernagel G, Chen YQ, Rief M et al.

Link to full article    

This study published in the European Heart Journal reveals a potential game-changer in cardiovascular health, finding an inverse relationship between levels of apolipoprotein C-II (ApoC-II) and cardiovascular mortality, suggesting that increasing ApoC-II could be a novel approach to reducing heart disease risk.

2) Clusters of prediabetes and type 2 diabetes stratify all-cause mortality in a cohort of participants undergoing invasive coronary diagnostics.
Cardiovasc Diabetol 2023; 22:211. Prystupa K, Delgado GE, Moissl AP et al.

Link to full article    

New metabolic clustering techniques reveal distinct subphenotypes in diabetes and prediabetes that significantly impact survival rates in patients evaluated for coronary heart disease, identifying high-risk individuals in need of specialised attention.

3) Triglyceride-glucose index is associated with the risk of chronic kidney disease progression in type 2 diabetes.
Endocrine 2023; 81:77-89. Duan S, Zhou M, Lu F et al.

Link to full article    

New research reveals that a higher Triglyceride-glucose (TyG) index is significantly associated with an increased risk of chronic kidney disease progression in patients with type 2 diabetes, emphasising the potential importance of targeting insulin sensitivity in early disease stages.

4) Stress hyperglycemia ratio and long-term prognosis in patients with acute coronary syndrome: A multicenter, nationwide study.
J Diabetes 2023; 15:557-568. Zeng G, Song Y, Zhang Z et al.

Link to full article    

Nationwide study reveals that elevated Stress Hyperglycemia Ratio (SHR) is significantly linked to long-term adverse cardiovascular events in patients with acute coronary syndrome, regardless of their diabetic status.

5) Biomarkers Associated With Severe COVID-19 Among Populations With High Cardiometabolic Risk: A 2-Sample Mendelian Randomization Study.
JAMA Netw Open 2023; 6:e2325914. Sood T, Perrot N, Chong M et al.

Link to full article   

Kidney injury molecule-1 (KIM-1) identified as a potential biomarker that reduces COVID-19 hospitalisation risk, especially among individuals with high BMI, opening the door for novel therapeutic approaches.

6) Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Circulation 2023; 148:651-660.Januzzi JL, Mohebi R, Liu Y et al.

Link to full article    

The CREDENCE trial reveals the significant prognostic value of multiple cardiorenal biomarkers in type 2 diabetes patients and shows how canagliflozin could alter their levels to mitigate health risks.